Sulphamethoxypyridazine for dermatitis herpetiformis, linear IgA disease and cicatricial pemphigoid.
One-hundred and sixty-eight cases of dermatitis herpetiformis were reviewed to compare the clinical response to and incidence of side-effects from dapsone and sulphamethoxypyridazine. Thirty-seven received sulphamethoxypyridazine (0.25-1.5 g/day) as a single agent therapy at some stage during their care and 161 had dapsone only (50-450 mg/day). Thirty of these patients received both drugs, but at different times. Both were highly effective in controlling the skin disease in 97% of patients on dapsone and 89% on sulphamethoxypyridazine. While 36 (22%) of dapsone-treated subjects had intolerable side effects warranting a change in therapy, this occurred in only five (13.5%) of those treated with sulphamethoxypyridazine. Sulphamethoxypyridazine was also effective as a single agent in three patients with linear IgA disease who had suffered adverse effects from dapsone, and in 10 out of 15 patients with oral and cutaneous lesions of cicatricial pemphigoid.
McFadden
J P
JP
Department of Dermatology, St Mary's Hospital, London, U.K.
Leonard
J N
JN
Powles
A V
AV
Rutman
A J
AJ
Fry
L
L
D000293:Adolescent; D000328:Adult; D000368:Aged; D003622:Dapsone / Q000009:adverse effects / Q000627:therapeutic use; D003874:Dermatitis Herpetiformis / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007070:Immunoglobulin A; D008297:Male; D008875:Middle Aged; D010390:Pemphigoid, Benign Mucous Membrane / Q000188:drug therapy*; D012872:Skin Diseases, Vesiculobullous / Q000188:drug therapy*; D013421:Sulfamethoxypyridazine / Q000009:adverse effects / Q000627:therapeutic use*
D007070:Immunoglobulin A; D003622:Dapsone; D013421:Sulfamethoxypyridazine